Clinical impact of different exosomes' protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy.
Riccardo GiampieriFrancesco PivaGiulia OcchipintiAlessandro BittoniAlessandra RighettiSilvia PagliarettaAlberto MurroneFrancesca BianchiConsuelo AmantiniMatteo GiuliettiGiulia RicciGiovanni PrincipatoGiorgio SantoniRossana BerardiStefano CascinuPublished in: PloS one (2019)
Pancreatic cancer patients exosomes express EpCAM, whose levels change during treatment. This represents a useful prognostic factor and also suggests that future treatment modalities who target EpCAM should be tested in pancreatic cancer patients selected by exosome EpCAM expression.
Keyphrases
- prognostic factors
- circulating tumor cells
- cell adhesion
- end stage renal disease
- mesenchymal stem cells
- stem cells
- chronic kidney disease
- ejection fraction
- newly diagnosed
- poor prognosis
- palliative care
- peritoneal dialysis
- squamous cell carcinoma
- locally advanced
- radiation therapy
- current status
- combination therapy
- patient reported
- rectal cancer